AI-assisted analysis based on the official CRS summary. Source version: Jun 29, 2026. Analysis updated: Sep 15, 2026.
01 — The Text
What.
- The bill modifies FDA oversight of compounded drugs—drugs mixed or altered to meet individual patient needs—which currently do not require FDA approval.
- It redefines when a compounded drug is considered an 'essentially copy' of a commercial drug: if it contains any active ingredient found in a commercial product AND no patient-specific change creates significant difference.
- The bill raises the allowable frequency for compounding such copies from 4 times per month to 20 times per month.
- It requires annual reporting from physicians, facilities, and pharmacies (excluding hospital-based ones) that compound for out-of-state patients more than 20 times per month.
- Large-scale outsourcing facilities that compound in bulk become subject to regular inspection and reporting requirements.
02 — The Stakes
So what?
- The bill expands permitted compounding activity while simultaneously increasing regulatory oversight through reporting and inspection requirements.
- The redefined 'essentially copy' standard narrows the current FDA definition by removing consideration of dosage strength and route of administration.
- Effects on drug availability, safety outcomes, cost, or patient access are not established in the official summary.
- The documented change is regulatory: increased monitoring paired with increased permissible compounding volume.
03 — The Path
Now what?
- Committee on Health, Education, Labor, and Pensions reported the bill with an amendment (July 27, 2026).
- Bill placed on Senate Legislative Calendar under General Orders, Calendar No. 524 (July 27, 2026).
- No scheduled floor vote or further action date is documented.
Legislative History
Actions.
- Jul 27, 2026 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 524.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 22, 2026 — Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Feb 5, 2026 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Feb 5, 2026 — Introduced in Senate